These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 7637143)

  • 1. Long-term survival among men with conservatively treated localized prostate cancer.
    Albertsen PC; Fryback DG; Storer BE; Kolon TF; Fine J
    JAMA; 1995 Aug 23-30; 274(8):626-31. PubMed ID: 7637143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 20-year outcomes following conservative management of clinically localized prostate cancer.
    Albertsen PC; Hanley JA; Fine J
    JAMA; 2005 May; 293(17):2095-101. PubMed ID: 15870412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.
    Albertsen PC; Hanley JA; Gleason DF; Barry MJ
    JAMA; 1998 Sep; 280(11):975-80. PubMed ID: 9749479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer and the Will Rogers phenomenon.
    Albertsen PC; Hanley JA; Barrows GH; Penson DF; Kowalczyk PD; Sanders MM; Fine J
    J Natl Cancer Inst; 2005 Sep; 97(17):1248-53. PubMed ID: 16145045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of conservative management of clinically localized prostate cancer.
    Chodak GW; Thisted RA; Gerber GS; Johansson JE; Adolfsson J; Jones GW; Chisholm GD; Moskovitz B; Livne PM; Warner J
    N Engl J Med; 1994 Jan; 330(4):242-8. PubMed ID: 8272085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
    Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
    J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
    J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.
    Patel AA; Chen MH; Renshaw AA; D'Amico AV
    JAMA; 2007 Oct; 298(13):1533-8. PubMed ID: 17911498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
    Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
    J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of co-morbidity on life expectancy among men with localized prostate cancer.
    Albertsen PC; Fryback DG; Storer BE; Kolon TF; Fine J
    J Urol; 1996 Jul; 156(1):127-32. PubMed ID: 8648773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.
    Potosky AL; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Jiang M; Tsai HT; Luta G; Keating NL; Smith MR; Van Den Eeden SK
    J Clin Oncol; 2014 May; 32(13):1324-30. PubMed ID: 24638009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
    Soulié M; Villers A; Richaud P; Prapotnich D; Ruffion A; Grosclaude P
    Prog Urol; 2001 Dec; 11(6):1195-204. PubMed ID: 11859652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
    Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
    Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy).
    Tewari A; Raman JD; Chang P; Rao S; Divine G; Menon M
    Urology; 2006 Dec; 68(6):1268-74. PubMed ID: 17169648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection.
    Egevad L; Granfors T; Karlberg L; Bergh A; Stattin P
    J Urol; 2002 Aug; 168(2):509-13. PubMed ID: 12131299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
    Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
    Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
    J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.